{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:12:57Z","timestamp":1791202377475,"version":"4.2.0"},"reference-count":151,"publisher":"Baishideng Publishing Group Inc.","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WJH"],"published-print":{"date-parts":[[2015]]},"DOI":"10.4254\/wjh.v7.i15.1936","type":"journal-article","created":{"date-parts":[[2015,7,27]],"date-time":"2015-07-27T07:48:42Z","timestamp":1437983322000},"page":"1936","source":"Crossref","is-referenced-by-count":18,"title":["Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a \u201cspecial population\u201d?"],"prefix":"10.4254","volume":"7","author":[{"given":"Drosos E","family":"Karageorgopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2060","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12247"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000432470.46379.dd"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-382"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2014.05.018"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61097-0"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis694"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Wiessing L, Likatavicius G, Hedrich D, Guarita B, van de Laar MJ, Vicente J. Trends in HIV and hepatitis C virus infections among injecting drug users in Europe, 2005 to 2010. Euro Surveill 2011;16.","DOI":"10.2807\/ese.16.48.20031-en"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078941"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2007.027334"},{"key":"ref10","unstructured":"Wandeler G, Rohrbach J, Metzner K, Fehr J, St&ouml;ckle M, Cavassini M, Ambrosioni J, Keiser O, Furrer H, Rauch A. Incident HCV Infections in the Swiss HIV Cohort Study: Natural History and Treatment Outcomes. Abstract 643 In: 21st Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA; 2014; Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.croiconference.org\/sessions\/incident-hcv-infections-swiss-hiv-cohort-study-natural-history-and-treatment-outcomes\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.croiconference.org\/sessions\/incident-hcv-infections-swiss-hiv-cohort-study-natural-history-and-treatment-outcomes<\/ext-link>."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Vanhommerig JW, Stolte IG, Lambers FAE, Geskus RB, van de Laar TJW, Bruisten SM, Schinkel J, Prins M. Hepatitis C Virus Incidence in the Amsterdam Cohort Study Among Men Who Have Sex With Men: 1984-2011. Abstract 673 In: 21st Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA; 2014; Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.croiconference.org\/sessions\/hepatitis-c-virus-incidence-amsterdam-cohort-study-among-men-who-have-sex-men-1984-2011\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.croiconference.org\/sessions\/hepatitis-c-virus-incidence-amsterdam-cohort-study-among-men-who-have-sex-men-1984-2011<\/ext-link>.","DOI":"10.1016\/S0168-8278(14)60094-5"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.02.006"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq200"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit197"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis404"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2012-050566"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12366"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.11.059"},{"key":"ref19","unstructured":"Bavinton BR, Jin F, Zablotska I, Prestage G, Grulich A. The Opposites Attract Study Team. Undetectable viral load is associated with increased unprotected anal intercourse in gay serodiscordant couples. Abstract MOLBPE30 In: 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Kuala Lumpur, Malaysia; 2013;."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283471cce"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-456.","DOI":"10.1001\/jama.284.4.450"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22375"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24370"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290424"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.","DOI":"10.1053\/gast.1997.v112.pm9024300"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.01.005"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994;84:1020-1023.","DOI":"10.1182\/blood.V84.4.1020.1020"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Daar ES, Lynn H, Donfield S, Gomperts E, Hilgartner MW, Hoots WK, Chernoff D, Arkin S, Wong WY, Winkler CA. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 2001;26:466-472.","DOI":"10.1097\/00126334-200104150-00011"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101760"},{"key":"ref30","unstructured":"European Medicines Agency. Harvoni. Summary of Product Characteristics [Internet]. [Cited 2014 Dec 26] Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/003850\/WC500177997.pdf\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/003850\/WC500177997.pdf<\/ext-link>."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1086\/587843"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)60942-9"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2014.17"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis367"},{"key":"ref35","unstructured":"Boesecke C, Ingiliz P, Mandorfer M, Schwarze-Zander C, Berger F, Valantin MA, Wasmuth JC, Reiberger T, Mauss S, Rockstroh JK, the NEAT study group. Is There Long-Term Evidence of Advanced Liver Fibrosis After Acute Hepatitis C in HIV Coinfection? Abstract 644 In: 21st Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA; 2014; Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.croiconference.org\/sessions\/there-long-term-evidence-advanced-liver-fibrosis-after-acute-hepatitis-c-hiv-coinfection\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.croiconference.org\/sessions\/there-long-term-evidence-advanced-liver-fibrosis-after-acute-hepatitis-c-hiv-coinfection<\/ext-link>."},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.179085"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.184473"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit357"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu167"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu525"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7844"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1829"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Merchante N, Gir&oacute;n-Gonz&aacute;lez JA, Gonz&aacute;lez-Serrano M, Torre-Cisneros J, Garc&iacute;a-Garc&iacute;a JA, Arizcorreta A, Ruiz-Morales J, Cano-Lliteras P, Lozano F, Mart&iacute;nez-Sierra C. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006;20:49-57.","DOI":"10.1097\/01.aids.0000198087.47454.e1"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21990"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.06.010"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000222"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62001-6"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833a0918"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.15.1632"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1086\/644771"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000059"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-010-0071-3"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23136"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12108"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2827"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2013.05.007"},{"key":"ref57","unstructured":"Mathews G, Bhagani S. The epidemiology and natural history of HIV\/HBV and HIV\/HCV co-infections. J HIV Ther 2003;8:77-84."},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.12.026"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.01.005"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004623"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1086\/600107"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23679"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.04.029"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1402351111"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098039"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2004.03255.x"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2336"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82974-0"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9071(199607)49:3&lt;242::AID-JMV14&gt;3.0.CO;2-E"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1038\/nm1511"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.03.022"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834dcec9"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2012.01051.x"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis919"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283574e94"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit033"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834e8805"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830e6d51"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-012-1546-5"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2419"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit779"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12106"},{"key":"ref83","unstructured":"EACS European AIDS Clinical Society. EACS Guidelines Version 7.0 2. [Updated 2014 Jun] Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html<\/ext-link>."},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000084"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12068"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis1007"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02323.x"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32834bd257"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040842"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1038\/nature04082"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23985"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05131.x"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010494"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.","DOI":"10.1056\/NEJMoa1012912"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu659"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000034"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4050"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1400986"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-234"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70149-X"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-2-201307160-00654"},{"key":"ref102","unstructured":"Rodriguez-Torres M, Rodriguez-Orengo J, Gaggar A, Shen G, Symonds B, McHutchison J, Gonzalez M. Sofosbuvir and Peginterferon alfa-2a\/RibavirinTreatment of na&iuml;ve Genotype 1-4 HCV infected patients that are co-infected with HIV. Abstract 714 2013; Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.natap.org\/2013\/IDSA\/IDSA_24.htm\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.natap.org\/2013\/IDSA\/IDSA_24.htm<\/ext-link>."},{"key":"ref103","unstructured":"Dieterich D, Tural C, Nelson M, Arasteh K, Soriano V, Guardiola J, Bhagani S, Rockstroh JK, Stern JO, Quinson A-M, on behalf of the STARTVerso4 Study Group. Faldaprevir plus pegylated interferon alfa-2a\/ribavirin in HIV\/HCV coinfection: STARTVerso4. Abstract #23 In: 21st Conference on Retroviruses and Opportunistic Infections (CROI). Boston, MA; 2014; Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.croiconference.org\/sessions\/faldaprevir-plus-pegylated-interferon-alfa-2aribavirin-hivhcv-co-infection-startverso4\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.croiconference.org\/sessions\/faldaprevir-plus-pegylated-interferon-alfa-2aribavirin-hivhcv-co-infection-startverso4<\/ext-link>."},{"key":"ref104","unstructured":"Dieterich D, Tural C, Nelson M, Arasteh K, Soriano V, Guardiola J, Bhagani S, Rockstroh JK, Stern JO, Quinson A-M, on behalf of the STARTVerso4 Study Group. Faldaprevir Plus Pegylated Interferon &alpha;-2a\/Ribavirin in HIV\/HCV Co infection: Abstract #681. STARTVerso4 In: (APASL) 23rd Conference of the Asian Pacific Association for the Study of the Liver. Brisbane, Australia; 2014; Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/apasl.info\/\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/apasl.info\/<\/ext-link>."},{"key":"ref105","unstructured":"Dieterich D, Rockstroh J, Orkin C, Gutierrez F, Klein MB, Reynes J, Jessner W, Lenz O, Peeters M, Beumont-Mauviel M. Simeprevir with pegylated interferon\/ribavirin in patients co-infected with chronic hepatitis C and HIV-1: week-24 interim analysis of the TMC435-C212 study. Abstract 154LB In: 20th Conference on Retroviruses and Opportunistic Infections (CROI). Atlanta, GA; 2013; Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.retroconference.org\/\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.retroconference.org\/<\/ext-link>."},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7734"},{"key":"ref107","unstructured":"Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, Massetto B, Gaggar A, Ni L, Svarovskaia E. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotypes 1, 2, 3 and 4 infection in patients co-infected with HIV (PHOTON-2). Abstract MOAB0105LB In: 20th International AIDS Conference. Melbourne, Australia; 2014; Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/pag.aids2014.org\/\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/pag.aids2014.org\/<\/ext-link>."},{"key":"ref108","unstructured":"Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Slim J, Gathe J, Ruane PJ, Wang C, Elion R. Safety and efficacy of ABT-450\/r\/ombitasvir, dasabuvir, and ribavirin in patients co-infected with hepatitis C and HIV-1. Abstract MOAB0104LB In: 20th International AIDS Conferenc. Melbourne, Australia; 2014; Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/pag.aids2014.org\/\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/pag.aids2014.org\/<\/ext-link>."},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)60016-7"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)60065-9"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12646"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"Morice Y, Cantaloube JF, Beaucourt S, Barbotte L, De Gendt S, Goncales FL, Butterworth L, Cooksley G, Gish RG, Beaugrand M. Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. J Med Virol 2006;78:1296-1303.","DOI":"10.1002\/jmv.20692"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214853"},{"key":"ref114","unstructured":"Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, P Mantry, C Moreno, D Ouzan, M Wright, LE Morano, R Buynak, M Bourli&egrave;re, T Hassanein, S Nishiguchi, J-H Kao, M Omata, SW Paik, DK Wong, E Tam, K Kaita, SV Feinman, JO Stern, M Garcia, AM Quinson, F Voss, J-P Gallivan, WO B&ouml;cher, P Ferenci, on behalf of the STARTVerso1 and STARTVerso2 Study Groups. A pooled analysis of two randomized, double-blind placebo-controlled Phase III trials (STARTVerso1&amp;2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment- na&iuml;ve patients with chronic hepatitis C genotype-1 infection. Abstract 1088 In: The Liver Meeting&reg;, 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 1 - 5 November. Washington, DC; 2013; Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.aasld.org\/\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.aasld.org\/<\/ext-link>."},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60494-3"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60538-9"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.058"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.109309"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)61403-3"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315722"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401561"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402869"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402454"},{"key":"ref125","doi-asserted-by":"crossref","unstructured":"Hezode C, Serfaty L, Vierling JM, Kugelmas M, Pearlman B, Sievert W, Ghesquiere W, Zuckerman E, Sund F, Howe A. Safety and efficacy of the all-oral regimen of MK-5172\/MK-8742 &plusmn; ribavirin in treatment-naive, non-cirrhotic, patients with hepatitis C virus genotype 1 infection: the C-WORTHY study. Abstract 10. UK: London; 2014; Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.journal-of-hepatology.eu\/\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.journal-of-hepatology.eu\/<\/ext-link>.","DOI":"10.1016\/S0168-8278(14)60012-X"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)60063-5"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.7085"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu662"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.05.001"},{"key":"ref130","unstructured":"AASLD\/IDSA\/IAS-USA. Recommendations for testing, managing, and treating hepatitis C [Internet]. [Cited 2014 Dec 28] Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.hcvguidelines.org\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.hcvguidelines.org<\/ext-link>."},{"key":"ref131","unstructured":"United States. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct- Acting Antiviral Drugs for Treatment. Draft Guidance. Revision 1; 2013; Available from: <ext-link ext-link-type=\"uri\" xlink:href=\"http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm225333.pdf\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\">http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm225333.pdf<\/ext-link>."},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328343443b"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit799"},{"key":"ref134","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32836381cc"},{"key":"ref135","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27192"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)60906-5"},{"key":"ref137","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis763"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12641"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32825eaba7"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis663"},{"key":"ref141","unstructured":"Blair JM, Fagan JL, Frazier EL, Do A, Bradley H, Valverde EE, McNaghten A, Beer L, Zhang S, Huang P. Behavioral and clinical characteristics of persons receiving medical care for HIV infection - Medical Monitoring Project, United States, 2009. MMWR Surveill Summ 2014;63 Suppl 5:1-22."},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283578b9b"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq048"},{"key":"ref144","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0142-1"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2014.0033"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-11-16"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2484"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14844-1"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12132"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26431"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.008"}],"container-title":["World Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v7\/i15\/1936.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T03:48:59Z","timestamp":1652932139000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.wjgnet.com\/1948-5182\/full\/v7\/i15\/1936.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":151,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.4254\/wjh.v7.i15.1936","relation":{},"ISSN":["1948-5182"],"issn-type":[{"value":"1948-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2015]]}}}